Sergio Marchini, PhD, Humanitas Research Hospital, Milan, Italy, presents findings from a Phase III MITO-16A/MaNGO-OV2A trial (NCT01706120) assessing the prognostic value of untargeted circulating tumor DNA (ctDNA) analysis. Multivariate analysis further confirmed the prognostic significance of plasma tumor fraction (TF) in progression-free survival (PFS). These results underscore the potential of liquid biopsy using untargeted low pass whole genome sequencing tools in predicting treatment response and patient outcomes in ovarian cancer. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
